Madrigal Pharmaceuticals acquires Pfizer

Madrigal Pharmaceuticals agreed to acquire Pfizer. Reported deal value: Undisclosed. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: New York City, New York, United States.

This page summarizes publicly available information about the transaction as of 2026-01-14. Figures and status may change as filings and press coverage update.

PFE Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer – ervogastat and two preclinical assets – as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis treatment space through leveraging early commercial success